Stereotaxis, Inc. (STXS) stock
Close on Nov 13, 2026Market cap $84.49MP/E –Yield –
Stereotaxis, Inc. saw revenue fall 5.5% to $30.07M over the twelve months to Jun 30, 2026. Free cash flow was -$15.50M. At the latest close the market valued the company at $84.49M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $84.49M
- P/E ratio
- –
- Price to sales
- 2.81
- Price to book
- 6.90
- Dividend yield
- –
- Free cash flow yield
- -18.35%
Fundamentals
- Revenue
- $30.07M
- Net income
- -$22.32M
- EPS, diluted
- -$0.24
- Free cash flow
- -$15.50M
- Book value per share
- $0.12
- Diluted shares
- 100M
Trading
- Next earnings
- Mar 8, 2027 (estimated, during market hours)
- Previous close
- $0.85
- Open
- $0.86
- Day's range
- $0.82 – $0.89
- Volume
- 1,609,105
- Average volume (20 days)
- 972,332
- Index membership
- Russell 2000 (since Sep 2024)
- Beta (5 years)
- 1.23
- 52-week range
- $0.80 – $2.86
- RSI (14 days)
- 36.3
- Volatility (1 year)
- 54.7%
- Relative volume
- 1.95×
- WACC
- 11.2%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | STXS | S&P 500 | Difference | STXS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.5% | -3.0% | −17.4 pts | ||
| 3 months | -38.9% | -2.8% | −36.1 pts | ||
| Year to date | -63.3% | +11.5% | −74.8 pts | ||
| 1 year | -62.4% | +13.5% | −75.8 pts | ||
| 3 years | -41.4% | +77.7% | −119.1 pts | -16.3% | +21.1% |
| 5 years | -87.1% | +72.6% | −159.7 pts | -33.6% | +11.5% |
| 10 years | +50.6% | +308.2% | −257.6 pts | +4.2% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Stereotaxis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Update
- Results
About Stereotaxis
Electromedical & Electrotherapeutic Apparatus
Stereotaxis designs, manufactures, and markets robotic systems, instruments, and information systems for interventional laboratories. Its proprietary Robotic Magnetic Navigation technology uses computer-controlled magnetic fields to directly steer the working tip of flexible catheters and interventional devices during endovascular procedures. The company primarily focuses on electrophysiology, particularly cardiac ablation procedures to treat arrhythmias, while also developing applications for coronary, neuro, and peripheral interventions. Its product portfolio features the Genesis RMN and GenesisX RMN Systems, Synchrony and SynX cath lab display and connectivity solutions, Odyssey systems, and Map-iT diagnostic catheters. Stereotaxis operates as a single business segment, serving electrophysiologists and hospitals worldwide.
Company profile, executives and historyStereotaxis stock: common questions
What is Stereotaxis's stock price?
STXS closed at $0.84 on Nov 13, 2026, down 0.80% on the day. Over the past 52 weeks it traded between $0.80 and $2.86.
What is Stereotaxis's market cap?
Stereotaxis was worth $84.49M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is STXS's P/E ratio?
Stereotaxis lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.24), so it has no meaningful P/E ratio.
How much revenue does Stereotaxis make?
Stereotaxis reported revenue of $30.07M for the twelve months to Jun 30, 2026, down 5.5% from a year earlier.
Does Stereotaxis pay a dividend?
No. Stereotaxis has not paid a cash dividend over the last twelve months.
When does Stereotaxis report earnings next?
Stereotaxis is expected to report Q4 FY2026 results on Mar 8, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has STXS stock performed over the past year?
Including dividends, STXS returned -62.4% over the past year, against +13.5% for the S&P 500.
How many STXS shares are sold short?
6M shares were sold short at the latest FINRA report, 6.96% of the float, or 8.4 days of average trading volume.
Who are Stereotaxis's competitors?
Companies most similar to Stereotaxis by business, industry and size include FOCL, CVRX, OBIO, SSII, ECOR.
See a number that looks wrong?